Irritable Bowel Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016

Irritable Bowel Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist’s new report, “Irritable Bowel Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global irritable bowel syndrome market. The report identifies the key trends shaping and driving the global irritable bowel syndrome market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global irritable bowel syndrome sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key driver and challenges of the global irritable bowel syndrome market. Its scope includes:

• Annualized global irritable bowel syndrome market revenues data from 2000 to 2009, forecast for seven years to 2016.
• Key geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include guanylate cyclase type C receptor agonists, serotonin receptors targets, corticotrophin releasing factor 1 receptor antagonists, NK receptor targets and 5-aminosalicylate targets.
• Analysis of the current and future market competition in the global irritable bowel syndrome market. Key market players covered include Sucampo Pharmaceuticals, Tillotts Pharma AG, GSK, Axcan Pharma, Salix Pharmaceuticals and Tioga Pharmaceuticals.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future irritable bowel syndrome market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global irritable bowel syndrome market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global irritable bowel syndrome market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global irritable bowel syndrome market landscape? - Identify, understand and capitalize.

1 Table of Contents
1 Table of contents
    1.1 List of Tables
    1.2 List of Figures
2 Irritable Bowel Syndrome: Market Characterization
    2.1 Overview
    2.2 Irritable Bowel Syndrome Market Size
    2.3 Irritable Bowel Syndrome Market Forecast and CAGR
    2.4 Drivers and Barriers for Irritable bowel syndrome Market

    2.4.1 Drivers
    2.4.2 Restraints

    2.5 Opportunity and Unmet Need
    2.6 Key Takeaway
3 Irritable Bowel Syndrome Market: Competitive Assessment
    3.1 Overview
    3.2 Strategic Competitor Assessment

    3.2.1 Lotronex (Alosetron)
    3.2.2 Amitiza (Lubiprostone)
    3.2.3 Colpermin (Peppermint Oil)
    3.2.4 Bentyl (Dicyclomine hydrochloride)

    3.3 Key Takeaway
4 Irritable Bowel Syndrome Market: Pipeline Assessment
    4.1 Overview
    4.2 Strategic Pipeline Assessment

    4.2.1 Technology Trends Analytical Framework

    4.3 Irritable Bowel Syndrome - Promising Drugs under Clinical Development
    4.4 Drugs under Clinical Development

    4.4.1 Linaclotide (Linaclotide Acetate)
    4.4.2 Asimadoline
    4.4.3 Xifaxan (Rifaximin)
    4.4.4 Bifantis (Bifidobacterium infantis 35624)
    4.4.5 LX-103
    4.4.6 YM060 (Ramosetron hydrochloride)

    4.5 Irritable Bowel Syndrome Market - Clinical Pipeline by Mechanism of Action
    4.6 Irritable Bowel Syndrome Pipeline - Pipeline by Clinical Phases of Development

    4.6.1 Irritable Bowel Syndrome Market - Phase III Clinical Pipeline
    4.6.2 Irritable Bowel Syndrome Market - Phase II Clinical Pipeline
    4.6.3 Irritable Bowel Syndrome Market - Phase I Clinical Pipeline
    4.6.4 Irritable Bowel Syndrome Market - Preclinical Pipeline
    4.6.5 Irritable Bowel Syndrome Market - Discovery

    4.7 Discontinued / Suspended Drugs for Irritable Bowel Syndrome
    4.8 Key Takeaway
5 Irritable Bowel Syndrome Market: Implications for Future Market Competition
6 Irritable Bowel Syndrome Market: Future Players in the Irritable Bowel Syndrome Market
    6.1 Introduction
    6.2 Ironwood pharmaceuticals and Forest laboratories

    6.2.1 Company Overview
    6.2.2 IBS pipeline portfolio

    6.3 Tioga Pharmaceuticals

    6.3.1 Company Overview
    6.3.2 IBS Pipeline Porfolio

    6.4 Alimentary Health Ltd & P & G

    6.4.1 Company Overview
    6.4.2 IBS Pipeline Portfolio

    6.5 Lexicon

    6.5.1 Company Overview
    6.5.2 IBS pipeline portfolio

    6.6 Salix Pharmaceuticals

    6.6.1 Overview
    6.6.2 IBS pipeline portfolio

    6.7 Astellas Pharma

    6.7.1 Overview
    6.7.2 IBS pipeline portfolio

7 IBS Market: Appendix
    7.1 Definitions
    7.2 Abbreviations
    7.3 Research Methodology

    7.3.1 Coverage
    7.3.2 Secondary Research
    7.3.3 Forecasting
    7.3.4 Primary Research
    7.3.5 Expert Panels

    7.4 Contact Us
    7.5 Disclaimer
    7.6 Sources
1.1 List of Tables
    Table 1: Global IBS Market, Revenues ($bn), 2001-2009
    Table 2: Global IBS Market, Revenues ($bn), 2009-2016
    Table 3: Five Efficacy Studies in Women
    Table 4: Major Marketed Products in the IBS Market, 2010
    Table 5 : IBS -Most Promising Drugs Under Clinical Development, 2010
    Table 6: IBS Market - Phase III Clinical Pipeline, 2010
    Table 7: IBS Market - Phase II Clinical Pipeline, 2010
    Table 8: IBS Market - Phase I Clinical Pipeline, 2010
    Table 9: IBS Market PreClinical Pipeline, 2010
    Table 10: IBS Market, Discovery Pipeline, 2010
    Table 11: Discontinued/Suspended Drugs for IBS, 2010
    Table 12: Ironwood Pharmaceuticals- IBS pipeline products, 2010
    Table 13: Tioga Pharmaceuticals - IBS pipeline products, 2010
    Table 14: Alimentary Health Ltd & P & G - IBS pipeline products, 2010
    Table 15: Lexicon - IBS pipeline portfolio, 2010
    Table 16: Salix Pharmaceutical - IBS pipeline portfolio, 2010
    Table 17: Astellas Pharma - IBS Pipeline Portfolio, 2010
1.2 List of Figures
    Figure 1: Global IBS Market, Revenues ($bn), 2001-2009
    Figure 2: Global IBS Market, Revenues ($bn), 2009-2016
    Figure 3: Opportunity and Unmet Need in the IBS Market, 2010
    Figure 4: Strategic Competitor Assessment of the Major Marketed Products IBS, 2010
    Figure 5: Technology Trends Analytic Framework of the IBS Pipeline, 2010
    Figure 6: Technology Trends Analytic Framework of IBS, Description, 2010
    Figure 7: IBS Market - Clinical Pipeline by Mechanism of Action, 2010
    Figure 8: IBS Pipeline by Phase of Clinical Development, 2010
    Figure 9: Implications for Future Market Competition in the IBS Market, 2010
    Figure 10: IBS Market - Clinical Pipeline by Company, 2010
    Figure 11: GlobalData Methodology, 2010
    Figure 12: GlobalData Market Forecasting Model, 2010